(19)
(11) EP 3 624 839 A1

(12)

(43) Date of publication:
25.03.2020 Bulletin 2020/13

(21) Application number: 18802489.7

(22) Date of filing: 16.05.2018
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61K 31/5517(2006.01)
C12Q 1/68(2018.01)
G01N 33/574(2006.01)
(86) International application number:
PCT/US2018/032945
(87) International publication number:
WO 2018/213430 (22.11.2018 Gazette 2018/47)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 17.05.2017 US 201762507636 P
21.06.2017 US 201762523112 P
31.10.2017 US 201762579779 P
08.12.2017 US 201762596377 P
19.04.2018 US 201862660096 P

(71) Applicant: Immunogen, Inc.
Waltham, MA 02451 (US)

(72) Inventors:
  • WALKER, Russell
    Dedham Massachusetts 02026 (US)
  • SLOSS, Callum
    Wakefield Massachusetts 01880 (US)
  • ZWEIDLER-MCKAY, Patrick
    Lincoln Massachusetts 01773 (US)
  • CULM-MERDEK, Kerry
    Natick Massachusetts 01760 (US)

(74) Representative: Nottrott, Stephanie 
Patentanwälte Isenbruck Bösl Hörschler PartG mbB Prinzregentenstraße 68
81675 München
81675 München (DE)

   


(54) ANTI-CD33 IMMUNOCONJUGATE DOSING REGIMENS